Premium
THR ‐687, a potent small molecule integrin antagonist, holds promise as a therapeutic approach for back‐of‐the‐eye vascular pathologies
Author(s) -
Van Hove I.,
Vanhove M.,
Porcu M.,
Barbeaux P.,
Feyen J.H.M.,
Vermassen E.
Publication year - 2017
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2017.0f075
Subject(s) - integrin , pharmacology , receptor , ex vivo , in vivo , angiogenesis , cytotoxicity , microbiology and biotechnology , cancer research , immunology , medicine , biology , in vitro , biochemistry
Purpose Pathologic neovascularization and vessel leakage are key drivers for vision loss in several back‐of‐the‐eye diseases, such as diabetic retinopathy and age‐related macular degeneration. In the eye, integrin receptors play an important role in (pathological) angiogenesis and vascular leakage. Blocking integrin receptors has the potential to inhibit these processes, independent of anti‐ VEGF responsiveness. In this study, we evaluated the integrin‐blocking and anti‐angiogenic properties of THR ‐687, a novel small molecule integrin antagonist. Methods Competition ELISA assays were used to assess the ability of THR ‐687 to compete with the binding of integrin receptors to their natural ligands. The inhibitory effect of THR ‐687 on the migration of human umbilical vein endothelial cells ( HUVEC s) was evaluated in the ORIS cell migration assay. The effect of THR ‐687 on blood vessel outgrowth was evaluated in an ex vivo mouse choroidal explant model. Cytotoxicity of THR ‐687 on human retinal microvascular endothelial cells ( HRMVEC s) was evaluated using the CellTox Green assay. The safety profile of THR ‐687 was further evaluated using hERG and genotoxicity assays. Results THR ‐687 was found to inhibit multiple integrin receptors belonging to the RGD class with IC 50 values in the low nanomolar range, including, but not limited to, α v β 3, α v β 5 and α 5 β 1. THR ‐687 potently inhibited the migration of HUVEC s in the ORIS system ( IC 50 of 82 ± 11 nM). Ex vivo choroidal vessel sprouting was dose‐dependently inhibited by THR ‐687 ( IC 50 of 1.50 ± 0.27 μ M). No relevant cytotoxicity signal was observed on HRMVEC s at concentrations ranging from 0.25 nM to 20 μ M, and in vitro pharmacological profiling studies indicated a good safety profile. Conclusions THR ‐687 is a potent drug candidate for the treatment of diabetic eye disease.